Buy (150 RUB)
Generate QR code
Open Access
Subscription or Fee Access
Long-term effects of treatment of acute lymphoblastic leukemia in childhood on the part of the musculoskeletal system
https://doi.org/10.33667/2078-5631-2024-24-63-66
Abstract
Effective treatment of leukemia in children has improved both the five-year and long-term survival of patients. An increase in life expectancy requires an assessment of the long-term effects of treatment. The use of antitumor drugs such as mercaptopurin, methotrexate, tyrosine kinase inhibitors, as well as glucocorticosteroids often negatively affect the musculoskeletal system, including bone mineralization, which can lead to fractures, necrosis, arthropathy and other lesions of the musculoskeletal system, Side effects of anticancer drugs, glucocorticosteroids on bone tissue are especially important in childhood, when the skeleton is being formed and their long-term negative effect on the musculoskeletal system is no less important. The assessment of long-term consequences will make it possible to develop timely preventive measures. KEYWORDS: bone tissue, antitumor therapy, leukemia, long-term effects of treatment.
About the Authors
N. D. Karseladze
Medical Center of the Airport of the MOW
Russian Federation
Russian Federation
Karseladze Natalia Dz., PhD Med, general practitioner
Moscow
N. V. Orlova
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Orlova Natalia V., DM Sci (habil.), professor at Dept of Faculty Therapy
Moscow
O. A. Tiganova
Pirogov Russian National Research Medical University; Morozovskaya Children`s City Clinical Hospital of the Department of Health of the City of Moscow»
Russian Federation
Russian Federation
Tiganova Olga A., PhD Med, associate professor at Dept of Hospital Pediatrics at Faculty of Pediatrics; pediatric oncologist-hematologist
Moscow
D. P. Sichinava
City Polyclinic № 9 of the Moscow Department of Health
Russian Federation
Russian Federation
Sichinava David P., PhD Med, deputy chief physician
Moscow
T. V. Nalegach
Clinic “NACPP”
Russian Federation
Russian Federation
Nalegach Tatyana V., general practitioner
Moscow
References
1. Valiev T. T., Shervashidze M.A., Belysheva T. S. Assessment of the toxicity of therapy for acute lymphoblastic leukemia according to the ALL IC-BFM 2002 protocol. Oncohematology. 2022; 17 (3): 137-159. (In Russ.). URL: https://cyberleninka.ru/article/n/otsenka-toksichnosti-terapii-ostrogo-limfoblastnogo-leykoza-po-protokolu-all-ic-bfm 2002 (дата обращения: 05.10.2024).
2. Textbook «Pediatrics» in 5 volumes / edited by D.Y. Ovsyannikov. Vol. 3. «Allergology, oncohematology, dermatology and venereology». Chap. «General issues of epidemiology, etiology, pathogenesis, diagnosis and therapy of leukemia», «Acute lymphoblastic leukemia». Moscow: RUDN, 2023. Pp. 205-236, 237-251. (In Russ.).
3. Hudson MM, Ehrhardt MJ, Bhakta N. et al. Approach for Classification and Severity Grading of Long-term and Late-Onset Health Events among Childhood Cancer Survivors in the St. Jude Lifetime Cohort. Cancer Epidemiol Biomarkers Prev. 2017 May; 26 (5): 666-674. DOI: 10.1158/1055-9965. EPI 16–0812
4. van Kalsbeek RJ, van der Pal HJH, Kremer LCM et al. European PanCareFollowUp Recommendations for surveillance of late effects of childhood, adolescent, and young adult cancer. Eur. J. Cancer. 2021 Sep; 154: 316-328. DOI: 10.1016/j.ejca.2021.06.004
5. Panina O. V., Semenova E. V., Markova I. V. et al. Modern ideas about the treatment of acute leukemia in children under 1 year old. Russian Journal of Pediatric Hematology and Oncology. 2019; 6 (2): 11-19. (In Russ.). URL: https://cyberleninka.ru/article/n/sovremennye-predstavleniya-o-terapii-ostrogo-leykoza-u-detey-do-1-goda (дата обращения: 05.10.2024).
6. Mulrooney D. A., Hyun G., Ness K. K. et al. The changing burden of long-term health outcomes in survivors of childhood acute lymphoblastic leukaemia: a retrospective analysis of the St Jude Lifetime Cohort Study. Lancet Haematol. 2019 Jun; 6 (6): e306-e316. DOI: 10.1016/S2352-3026(19)30050-X
7. Oeffinger K. C., Mertens A. C., Sklar C.A. et al. Childhood Cancer Survivor Study. Chronic health conditions in adult survivors of childhood cancer. N. Engl. J. Med. 2006 Oct 12; 355 (15): 1572-82. DOI: 10.1056/NEJMsa060185
8. Choi YJ. Cancer treatment-induced bone loss. Korean J. Intern. Med. 2024 Sep; 39 (5): 731-745. DOI: 10.3904/kjim.2023.386
9. Bürger B., Beier R., Zimmermann M. et al. Beck JD, Reiter A, Schrappe M. Osteonecrosis: a treatment related toxicity in childhood acute lymphoblastic leukemia (ALL)-experiences from trial ALL-BFM 95. Pediatr Blood Cancer. 2005 Mar; 44 (3): 220- 5. DOI: 10.1002/pbc.20244
10. Kadan-Lottick NS, Dinu I, Wasilewski-Masker K. et al. Osteonecrosis in adult survivors of childhood cancer: a report from the childhood cancer survivor study. J. Clin. Oncol. 2008 Jun 20; 26 (18): 3038-45. DOI: 10.1200/JCO.2007.14.9088
11. Yamanishi AD, Determan D, Kuo DJ. Dose-Related Effect of Chemotherapy on Bone Mineral Density Among Pediatric Acute Lymphoblastic Leukemia Survivors. J. Pediatr. Pharmacol. Ther. 2024; 29 (1): 53-60. DOI: 10.5863/1551-6776-29.1.53
12. Wasilewski-Masker K, Kaste SC, Hudson MM. et al. Bone mineral density deficits in survivors of childhood cancer: long-term follow-up guidelines and review of the literature. Pediatrics. 2008 Mar; 121 (3): e705-13. DOI: 10.1542/peds.2007-1396.
Review
For citations:
Karseladze N.D., Orlova N.V., Tiganova O.A., Sichinava D.P., Nalegach T.V. Long-term effects of treatment of acute lymphoblastic leukemia in childhood on the part of the musculoskeletal system. Medical alphabet. 2024;(24):63-66. (In Russ.) https://doi.org/10.33667/2078-5631-2024-24-63-66
Views:
83
Email this article 